Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Formycon is a leading, independent German developer of high-quality biosimilar drugs. The company focuses on therapies in ophthalmology, immunology, and other serious chronic diseases, with the mission to provide patients worldwide with access to affordable, life-enhancing medicines. Formycon leverages its extensive expertise in analytics, process development, and clinical research, along with strategic partnerships, to advance its robust pipeline of biosimilar candidates.
Serves as the central hub for Formycon's research and development, corporate governance, clinical trial management, and strategic business operations for its global biosimilar programs.
State-of-the-art laboratory and office facilities situated within the renowned Martinsried biotech cluster, one of Europe's leading life science hubs, fostering collaboration and innovation.
A dynamic, science-driven, and innovative environment that values expertise, collaboration, precision, and quality. Employees are typically passionate about contributing to medical advancements and improving patient access to affordable treatments.
The headquarters is pivotal for Formycon's mission, driving the development of its biosimilar pipeline and managing global partnerships. Its strategic location in the Martinsried biotech cluster provides access to top talent, research institutions, and industry networks.
Formycon operates with a global outlook, primarily supporting its worldwide mission through a network of international partners for clinical development, manufacturing, and commercialization of its biosimilar candidates. While its core research and development activities are centralized at its German headquarters, Formycon's products are intended for global markets, including Europe, North America, and other key regions, to ensure broad patient access to its therapies.
Fraunhoferstraße 22
Planegg/Martinsried
Bavaria
Germany
Address: Lochhamer Str. 15, 82152 Planegg/Martinsried, Germany
Strengthens Formycon's development pipeline and operational capacity within the German biotech ecosystem, focusing on specialized aspects of biosimilar development and potentially market strategies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Formycon AG' leadership includes:
Formycon AG has been backed by several prominent investors over the years, including:
Formycon significantly reshaped its executive team over the past 12-18 months, appointing a new CEO (via internal role change to sole CEO), CFO, CBO, and CSO. These changes are aimed at steering the company through its next phase of growth, development, and commercialization of its biosimilar pipeline.
Discover the tools Formycon AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Formycon AG commonly uses the 'firstname.lastname@formycon.com' email format for its employees. This is a standard pattern for many German and European companies.
firstname.lastname@formycon.com
Format
stefan.glombitza@formycon.com
Example
85%
Success rate
formycon.com • May 23, 2024
Formycon and its commercialization partner Fresenius Kabi announced the launch of FYB201 (ranibizumab), a biosimilar to Lucentis®, in Canada for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME)....more
formycon.com • April 25, 2024
Formycon AG reported a successful fiscal year 2023 with significant progress in its biosimilar pipeline and positive financial results. The company provided an optimistic outlook for 2024, expecting further revenue growth from product commercialization and milestone payments....more
formycon.com • October 26, 2023
Formycon AG announced the expansion of its Management Board with the appointment of Nicola Mikulcik as Chief Business Officer (CBO) and Dr. Andreas Seidl as Chief Scientific Officer (CSO), effective November 1, 2023, to support the company's growth strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Formycon AG, are just a search away.